Merck Announces Collaboration With Theravance and 3 Dow Movers to Track
The Coca-Cola Company (NYSE:KO) has posted figures for the third quarter that indicate well-balanced growth in volume all around the world with 2 percent growth in all geographic operating groups as well as in developed markets and 7 percent in emerging markets. Solid growth in key developed markets included 2 percent in North America, and also in Japan, with 1 percent in Europe, which posted growth across all business divisions in the quarter. Moreover, the company delivered impressive volume growth in key emerging markets like Thailand with 19 percent and India with 15 percent in the period. Global sparkling beverage volume rose by 3 percent in the quarter and also year-to-date. Eurasia and Africa group volume grew by 11 percent in the quarter and year-to-date. Europe’s volume grew 1 percent in the quarter, while Latin America volume increased by 5 percent both in the quarter and year-to-date. Lastly, North America volume grew by 2 percent in the quarter and year-to-date as well.
Merck & Co. (NYSE:MRK) and Theravance (NASDAQ:THRX) are collaborating to discover, develop and commercialize novel small molecule therapeutics aimed at the treatment of hypertension and heart failure. In return, Merck is receiving a global exclusive license to its therapeutic candidates. Theravance will get a $5 million upfront payment and research funding and will be eligible for milestone payments to total as high as $148 million for the first indication and royalties on worldwide net sales of any products generated from the collaboration.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Microsoft Corporation (NASDAQ:MSFT) has released details in regards to its tablet PC Microsoft Surface. The device with Windows RT will at first be available in three SKUs: a 32 gigbyte version priced at $499, a 32 gigabyte version bundled with a black Touch Cover at $599, and a version with 64 gigabyte bundled with a black Touch Cover at $699. Accessories will include Touch Covers at $119.99. Consumers will be able to buy Surface beginning October 26th, at all Microsoft Store locations within the United States and Canada. Also, Surface will be on sale online in eight markets across the world including the United Kingdom, Canada, France, Australia, China, Germany, Hong Kong, and the United States.
Pfizer (NYSE:PFE) has completed a double-blind, placebo-controlled, randomized clinical trial that was designed to evaluate the efficacy and safety of Chantix/Champix 1 mg BID, in comparison to placebo, for smoking cessation in patients having a past or present diagnosis of Major Depressive Disorder. The trial met its primary and secondary efficacy endpoints. Additionally, psychiatric scales included for safety assessments did not indicate a difference between varenicline and placebo.